Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology

Ravindran Kanesvaran(University of Ioannina), Vincent Launay‐Vacher(Sorbonne Université), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Toni K. Choueiri(Harvard University), Olivia Le Saux(Hospices Civils de Lyon), Florian Scotté(Université Paris-Saclay), Joaquim Bellmunt(Dana-Farber Cancer Institute)
The Lancet Oncology
June 1, 2018
10.1016/s1470-2045(18)30125-6
Cited by 62

Related Papers

The Immune Landscape of Cancer
|Immunity|2018|6.2k
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k